Market Cap 3.84B
Revenue (ttm) 2.79B
Net Income (ttm) -116.89M
EPS (ttm) N/A
PE Ratio 18.28
Forward PE 16.93
Profit Margin -4.18%
Debt to Equity Ratio -23.41
Volume 1,465,658
Avg Vol 1,741,132
Day's Range N/A - N/A
Shares Out 314.36M
Stochastic %K 70%
Beta 1.36
Analysts Strong Sell
Price Target $13.80

Company Profile

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and r...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 908 947 3120
Fax: 908 947 3146
Address:
400 Crossing Boulevard, 3rd Floor, Bridgewater, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 7:41 AM
Actionable Trade Alert for $AMRX: Market Context: $AMRX is currently trading at $12.21, showing a stable price action within the last 60 days, with a high of $12.68 and a low of $9.49. The RSI at 55.24 indicates a neutral to slightly bullish momentum, suggesting potential for upward movement. Directional Bias: The price is above both the 30-day MA (11.85) and 50-day MA (11.19), indicating a bullish trend. The proximity to the 60-day high suggests that a breakout could occur if buying momentum persists. Trade Plan: - Suggested Entry: $12.25 (slightly above the last close to confirm momentum) - Stop Loss: $11.80 (below the 30-day MA for protection) - Take Profit Targets: 1. $12.75 (4% gain) 2. $13.00 (6% gain) 3. $14.30 (17% gain) This plan offers a potential ROI of over 17% on the third target. Monitor price action closely for adjustments. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:34 AM
Actionable Trade Alert for $AMRX: Market Context: $AMRX is currently trading at $12.23, showing bullish momentum as it approaches the recent 60-day high of $12.68. The RSI of 62.59 indicates that the stock is nearing overbought territory but still has room for upward movement. The MA30 at $11.77 and MA50 at $11.15 suggest strong support levels, reinforcing a bullish outlook. Directional Bias: The stock is trending upward, with the current price above both moving averages, indicating potential for further gains. The proximity to the 60D high supports a bullish bias. Trade Plan: - Suggested Entry: $12.25 - Stop Loss: $11.80 (protects against downside) - Take Profit Targets: 1. $12.60 (2.86% ROI) 2. $13.00 (6.28% ROI) 3. $14.35 (17.31% ROI) This strategy aims for a minimum of 17% ROI on the third target while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
tamperson
tamperson Dec. 12 at 12:30 AM
$AMRX Jump in, under accumulation. Good / increasing daily volume and After-Hour volume. MM’s keeping it at $12 to $12.25 allowing friends to take a healthy position before next leg up.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 10 at 5:43 PM
$AMRX Current Stock Price: $11.97 Contracts to trade: $10 AMRX Dec 19 2025 Call Entry: $1.20 Exit: $2.28 ROI: 90% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:37 AM
Actionable Trade Alert for $AMRX: Market Context: $AMRX is currently trading at $11.97, showing a bullish sentiment with an RSI of 57.55, indicating potential for upward movement. The price is above the 30-day moving average (MA30) of $11.65 and the 50-day moving average (MA50) of $11.07, reinforcing a positive directional bias. Trade Plan: - Suggested Entry: $11.97 - Stop Loss: $11.50 (Risking $0.47, approximately 3.9%) - Take Profit Targets: 1. Target 1: $12.30 (Approx. 2.8% ROI) 2. Target 2: $12.68 (Approx. 5.9% ROI) 3. Target 3: $14.00 (Approx. 17.5% ROI) With the 60-day high at $12.68 and a potential breakout above this level, the third target offers a significant return. Monitor the price action closely as it approaches these levels. For further insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
notreload_ai
notreload_ai Dec. 9 at 9:25 PM
The FDA has approved $AMRX new single- and multi-dose epinephrine vials, expanding access to a critical emergency medicine used for allergic reactions and septic shock in hospitals and acute care settings. https://notreload.xyz/fda-oks-amneal-epinephrine-vials-for-emergency-care/
0 · Reply
G101SPM
G101SPM Dec. 9 at 9:10 PM
$AMRX 11.97 bid Holding long position https://stocktwits.com/G101SPM/message/637839332 BRIEF: Co announces that the FDA has approved the company's epinephrine injection USP, 1 mg/mL (1 mL), in single-dose vials and 1 mg/mL (30 mL) multi-dose vials. This medicine is a critical therapy utilized by hospitals, emergency departments and other acute care facilities for patient care.
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 3:20 PM
Barclays has updated their rating for Amneal Pharmaceuticals ( $AMRX ) to Overweight with a price target of 15.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 9 at 12:26 AM
Actionable Trade Alert for $AMRX: Market Context: $AMRX is currently trading at $11.91, showing a strong position within its recent price range. The RSI at 56.66 indicates bullish momentum, while the MA30 at $11.59 and MA50 at $11.03 suggest a positive trend as the price is above these moving averages. Directional Bias: With the 60D high at $12.68 and a low of $9.49, the stock has room to appreciate. The current price is closer to the high, indicating potential for upward movement. The ATR of $0.33 suggests moderate volatility, allowing for reasonable price swings. Trade Plan: - Suggested Entry: $11.91 - Stop Loss: $11.50 (3.5% risk) - Take Profit Targets: 1. $12.20 (2.4% gain) 2. $12.50 (4.9% gain) 3. $13.95 (17.1% gain) This plan offers a structured approach with a potential ROI of over 17% on the third target. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:25 AM
Actionable Trade Alert for $AMRX: Market Context: $AMRX is currently trading at $11.94, showing strength as it approaches its 60D high of $12.68. The RSI at 59.59 indicates bullish momentum without being overbought, suggesting potential for further gains. The price is above both the 30-day MA of $11.49 and the 50-day MA of $10.94, reinforcing a bullish trend. Directional Bias: Given the current price position and the RSI, we are bullish on $AMRX. The price is within a favorable range, having recently bounced off the 30-day MA, which can act as support. Trade Plan: - Suggested Entry: $11.95 - Stop Loss: $11.50 (approximately 3.8% below entry) - Take Profit Targets: 1. $12.30 (3% gain) 2. $12.60 (5.5% gain) 3. $14.00 (17.5% gain) This trade plan offers a solid risk-reward ratio with a potential ROI exceeding 17% on the third target. Monitor closely and adjust as necessary. https://privateprofiteers.com
0 · Reply
Latest News on AMRX
Amneal to Participate in Upcoming Investor Conferences

Dec 2, 2025, 8:00 AM EST - 13 days ago

Amneal to Participate in Upcoming Investor Conferences


Amneal Receives U.S. FDA Approval for Iohexol Injection

Nov 13, 2025, 4:01 PM EST - 4 weeks ago

Amneal Receives U.S. FDA Approval for Iohexol Injection


Amneal Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 6:00 AM EDT - 6 weeks ago

Amneal Reports Third Quarter 2025 Financial Results


Amneal to Report Third Quarter 2025 Results on October 30, 2025

Sep 30, 2025, 4:05 PM EDT - 2 months ago

Amneal to Report Third Quarter 2025 Results on October 30, 2025


Amneal (AMRX) Q2 EPS Jumps 56%

Aug 5, 2025, 4:39 PM EDT - 4 months ago

Amneal (AMRX) Q2 EPS Jumps 56%


Amneal Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 6:00 AM EDT - 4 months ago

Amneal Reports Second Quarter 2025 Financial Results


Amneal to Report Second Quarter 2025 Results on August 5, 2025

Jul 9, 2025, 8:00 AM EDT - 5 months ago

Amneal to Report Second Quarter 2025 Results on August 5, 2025


Amneal to Participate at Upcoming Investor Conferences in June

May 29, 2025, 4:05 PM EDT - 7 months ago

Amneal to Participate at Upcoming Investor Conferences in June


US FDA approves Amneal's migraine treatment

May 15, 2025, 8:16 AM EDT - 7 months ago

US FDA approves Amneal's migraine treatment


Amneal Reports First Quarter 2025 Financial Results

May 2, 2025, 6:00 AM EDT - 8 months ago

Amneal Reports First Quarter 2025 Financial Results


Amneal to Report First Quarter 2025 Results on May 2, 2025

Apr 8, 2025, 4:05 PM EDT - 8 months ago

Amneal to Report First Quarter 2025 Results on May 2, 2025


Amneal to Participate at Upcoming Investor Conference

Mar 10, 2025, 4:05 PM EDT - 10 months ago

Amneal to Participate at Upcoming Investor Conference


Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 28, 2025, 6:00 AM EST - 10 months ago

Amneal Reports Fourth Quarter and Full Year 2024 Financial Results


Amneal to Participate at Upcoming Investor Conferences

Dec 4, 2024, 8:00 AM EST - 1 year ago

Amneal to Participate at Upcoming Investor Conferences


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 7:41 AM
Actionable Trade Alert for $AMRX: Market Context: $AMRX is currently trading at $12.21, showing a stable price action within the last 60 days, with a high of $12.68 and a low of $9.49. The RSI at 55.24 indicates a neutral to slightly bullish momentum, suggesting potential for upward movement. Directional Bias: The price is above both the 30-day MA (11.85) and 50-day MA (11.19), indicating a bullish trend. The proximity to the 60-day high suggests that a breakout could occur if buying momentum persists. Trade Plan: - Suggested Entry: $12.25 (slightly above the last close to confirm momentum) - Stop Loss: $11.80 (below the 30-day MA for protection) - Take Profit Targets: 1. $12.75 (4% gain) 2. $13.00 (6% gain) 3. $14.30 (17% gain) This plan offers a potential ROI of over 17% on the third target. Monitor price action closely for adjustments. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:34 AM
Actionable Trade Alert for $AMRX: Market Context: $AMRX is currently trading at $12.23, showing bullish momentum as it approaches the recent 60-day high of $12.68. The RSI of 62.59 indicates that the stock is nearing overbought territory but still has room for upward movement. The MA30 at $11.77 and MA50 at $11.15 suggest strong support levels, reinforcing a bullish outlook. Directional Bias: The stock is trending upward, with the current price above both moving averages, indicating potential for further gains. The proximity to the 60D high supports a bullish bias. Trade Plan: - Suggested Entry: $12.25 - Stop Loss: $11.80 (protects against downside) - Take Profit Targets: 1. $12.60 (2.86% ROI) 2. $13.00 (6.28% ROI) 3. $14.35 (17.31% ROI) This strategy aims for a minimum of 17% ROI on the third target while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
tamperson
tamperson Dec. 12 at 12:30 AM
$AMRX Jump in, under accumulation. Good / increasing daily volume and After-Hour volume. MM’s keeping it at $12 to $12.25 allowing friends to take a healthy position before next leg up.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 10 at 5:43 PM
$AMRX Current Stock Price: $11.97 Contracts to trade: $10 AMRX Dec 19 2025 Call Entry: $1.20 Exit: $2.28 ROI: 90% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:37 AM
Actionable Trade Alert for $AMRX: Market Context: $AMRX is currently trading at $11.97, showing a bullish sentiment with an RSI of 57.55, indicating potential for upward movement. The price is above the 30-day moving average (MA30) of $11.65 and the 50-day moving average (MA50) of $11.07, reinforcing a positive directional bias. Trade Plan: - Suggested Entry: $11.97 - Stop Loss: $11.50 (Risking $0.47, approximately 3.9%) - Take Profit Targets: 1. Target 1: $12.30 (Approx. 2.8% ROI) 2. Target 2: $12.68 (Approx. 5.9% ROI) 3. Target 3: $14.00 (Approx. 17.5% ROI) With the 60-day high at $12.68 and a potential breakout above this level, the third target offers a significant return. Monitor the price action closely as it approaches these levels. For further insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
notreload_ai
notreload_ai Dec. 9 at 9:25 PM
The FDA has approved $AMRX new single- and multi-dose epinephrine vials, expanding access to a critical emergency medicine used for allergic reactions and septic shock in hospitals and acute care settings. https://notreload.xyz/fda-oks-amneal-epinephrine-vials-for-emergency-care/
0 · Reply
G101SPM
G101SPM Dec. 9 at 9:10 PM
$AMRX 11.97 bid Holding long position https://stocktwits.com/G101SPM/message/637839332 BRIEF: Co announces that the FDA has approved the company's epinephrine injection USP, 1 mg/mL (1 mL), in single-dose vials and 1 mg/mL (30 mL) multi-dose vials. This medicine is a critical therapy utilized by hospitals, emergency departments and other acute care facilities for patient care.
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 3:20 PM
Barclays has updated their rating for Amneal Pharmaceuticals ( $AMRX ) to Overweight with a price target of 15.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 9 at 12:26 AM
Actionable Trade Alert for $AMRX: Market Context: $AMRX is currently trading at $11.91, showing a strong position within its recent price range. The RSI at 56.66 indicates bullish momentum, while the MA30 at $11.59 and MA50 at $11.03 suggest a positive trend as the price is above these moving averages. Directional Bias: With the 60D high at $12.68 and a low of $9.49, the stock has room to appreciate. The current price is closer to the high, indicating potential for upward movement. The ATR of $0.33 suggests moderate volatility, allowing for reasonable price swings. Trade Plan: - Suggested Entry: $11.91 - Stop Loss: $11.50 (3.5% risk) - Take Profit Targets: 1. $12.20 (2.4% gain) 2. $12.50 (4.9% gain) 3. $13.95 (17.1% gain) This plan offers a structured approach with a potential ROI of over 17% on the third target. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:25 AM
Actionable Trade Alert for $AMRX: Market Context: $AMRX is currently trading at $11.94, showing strength as it approaches its 60D high of $12.68. The RSI at 59.59 indicates bullish momentum without being overbought, suggesting potential for further gains. The price is above both the 30-day MA of $11.49 and the 50-day MA of $10.94, reinforcing a bullish trend. Directional Bias: Given the current price position and the RSI, we are bullish on $AMRX. The price is within a favorable range, having recently bounced off the 30-day MA, which can act as support. Trade Plan: - Suggested Entry: $11.95 - Stop Loss: $11.50 (approximately 3.8% below entry) - Take Profit Targets: 1. $12.30 (3% gain) 2. $12.60 (5.5% gain) 3. $14.00 (17.5% gain) This trade plan offers a solid risk-reward ratio with a potential ROI exceeding 17% on the third target. Monitor closely and adjust as necessary. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 11:00 PM
Actionable Trade Alert for $AMRX: Market Context: $AMRX is currently trading at $11.94, showing strength as it approaches its 60D high of $12.68. The RSI at 59.59 indicates bullish momentum without being overbought, suggesting potential for further gains. The price is above both the 30-day MA of $11.49 and the 50-day MA of $10.94, reinforcing a bullish trend. Directional Bias: Given the current price position and the RSI, we are bullish on $AMRX. The price is within a favorable range, having recently bounced off the 30-day MA, which can act as support. Trade Plan: - Suggested Entry: $11.95 - Stop Loss: $11.50 (approximately 3.8% below entry) - Take Profit Targets: 1. $12.30 (3% gain) 2. $12.60 (5.5% gain) 3. $14.00 (17.5% gain) This trade plan offers a solid risk-reward ratio with a potential ROI exceeding 17% on the third target. Monitor closely and adjust as necessary. https://privateprofiteers.com
0 · Reply
Digger75
Digger75 Dec. 3 at 2:18 PM
0 · Reply
G101SPM
G101SPM Dec. 1 at 9:07 PM
$AMRX $12.35 bid. Holding long position at $8.20 https://stocktwits.com/G101SPM/message/583493657 CHAMNGE EXIT TO $19.00 (long term) FROM $16.00. BRIEF: Today announced the U.S. Food and Drug Administration (FDA) has approved the Company's cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. The product is the generic equivalent of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, a registered trademark of Allergan, an AbbVie company.
0 · Reply
ZacksResearch
ZacksResearch Nov. 28 at 4:02 PM
$ANIP vs. $AMRX — one of these niche drugmakers is shaping up as the clear momentum play. ANI Pharmaceuticals is riding rare-disease strength, with surging Cortrophin Gel sales giving it the stronger growth profile compared to its more diversified rival. Full breakdown here 👉 https://www.zacks.com/stock/news/2797189/anip-vs-amrx-which-niche-drugmaker-is-the-better-pick?cid=sm-stocktwits-2-2797189-teaser-22735&ADID=SYND_STOCKTWITS_TWEET_2_2797189_TEASER_22735
0 · Reply
ZacksResearch
ZacksResearch Nov. 28 at 3:02 PM
$ANIP vs. $AMRX: Which stock has the edge? 🏆 ANIP's rare disease sales are booming, with Cortrophin Gel sales expected to soar 75-78% over the prior year for 2025 📈. Meanwhile, AMRX faces margin pressures despite its diversified model 🤔. Discover why ANIP holds the advantage right now 👉 https://www.zacks.com/stock/news/2797189/anip-vs-amrx-which-niche-drugmaker-is-the-better-pick?cid=sm-stocktwits-2-2797189-body-22729&ADID=SYND_STOCKTWITS_TWEET_2_2797189_BODY_22729
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Nov. 13 at 9:49 PM
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 13 at 12:10 PM
$AMRX Share Price: $11.90 Contract Selected: Jun 18, 2026 $10 Calls Buy Zone: $2.31 – $2.85 Target Zone: $3.73 – $4.56 Potential Upside: 52% ROI Time to Expiration: 216 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
tamperson
tamperson Nov. 11 at 11:24 PM
$AMRX Congrats to AMRX on the new 12 month high stock price today. Hope the company can increase the price from here.
0 · Reply
10sense
10sense Nov. 11 at 7:18 PM
0 · Reply
topstockalerts
topstockalerts Nov. 7 at 7:03 PM
S&P Global Ratings revised its outlook on Amneal Pharmaceuticals Inc. to positive from stable while affirming the company’s ‘B+’ credit rating. The agency expects leverage to fall below 4x by 2026, following stronger-than-expected financial results through Q3 2025. Leverage has already improved to 4.2x and is projected to decline to 4.1x in 2025 and 3.7x in 2026. S&P said the improvement is driven by new product launches, including Crexont, a branded Parkinson’s therapy introduced in September 2024, which could reach peak sales of about $500 million by 2030. Amneal has cut leverage sharply from 8.5x in 2019 after founders Chirag and Chintu Patel returned and adopted a more conservative financial policy. Management aims to reduce net leverage below 3x by 2027. $AMRX
0 · Reply
d_risk
d_risk Nov. 7 at 12:16 AM
$AMRX - Amneal Pharmaceuticals Inc. Class A Common Stock - 10Q - Updated Risk Factors AMRX flags a new risk: a U.S. government shutdown could disrupt regulatory approvals, operations, and financial performance. #Pharmaceuticals #FinancialImpact #OperationalRisk #GovernmentShutdown #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/AMRX/10-Q/2025-11-06
0 · Reply
Doozio
Doozio Nov. 6 at 4:36 AM
$AMRX it was always 🐒🍌🧠⏰♾️
0 · Reply